TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32946077

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg, Cialis®)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both treatments (Tadalafil and Placebo)
Number of subjects: 12
Study: 34129153

Group type: EXPERIMENTAL
Intervention: Dabrafenib–trametinib
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 1

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 1
Study: 33491369

Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (β‐TCP/HA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hydroxyapatite (HA)
Number of subjects: 20
Study: 35144179

Group type: COMPARATOR
Intervention: Parallel group (SA 0°−3°)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lordotic group (SA > 3°)
Number of subjects: 160
Study: 34812472

Group type: EXPERIMENTAL
Intervention: Combination taping
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ankle foot orthosis
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (conventional physical therapy)
Number of subjects: 36
Study: 616642085

Group type: EXPERIMENTAL
Intervention: Iron intervention (point-of-use fortification with micronutrient powders containing vitamins and minerals with iron)
Number of subjects: 1943

Group type: COMPARATOR
Intervention: No-iron group (control)
Number of subjects: 1943

Group type: EXPERIMENTAL
Intervention: Both groups (combined analysis)
Number of subjects: 1943
Study: 35720389

Group type: EXPERIMENTAL
Intervention: Intranasal anti-SARS-CoV-2 RBD IgY
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 33541100

Group type: EXPERIMENTAL
Intervention: Enrolled group
Number of subjects: 2190

Group type: COMPARATOR
Intervention: Nonenrolled group
Number of subjects: 2190

Group type: COMPARATOR
Intervention: Eligible group
Number of subjects: 2190

Group type: COMPARATOR
Intervention: Ineligible group
Number of subjects: 2190
Study: 36113576

Group type: EXPERIMENTAL
Intervention: Group prenatal care
Number of subjects: 2350

Group type: EXPERIMENTAL
Intervention: Group prenatal care (Black participants)
Number of subjects: 2350
Study: 32681118

Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise (MICE) at 24.6% POpeak
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE) at 70% POpeak
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of MICE and HIIE
Number of subjects: 10
Study: 34259850

Group type: EXPERIMENTAL
Intervention: Chuna manual therapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care (electrotherapy and oral medication)
Number of subjects: 108
Study: 35443106

Group type: EXPERIMENTAL
Intervention: AZD7442 (300 mg, two consecutive intramuscular injections of tixagevimab and cilgavimab)
Number of subjects: 5197

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 5197

Group type: EXPERIMENTAL
Intervention: AZD7442 (300 mg)
Number of subjects: 5197
Study: 34219259

Group type: EXPERIMENTAL
Intervention: Xenogeneic collagen matrix (XCM)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Free gingival grafts (FGG)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: XCM
Number of subjects: 26

Group type: COMPARATOR
Intervention: FGG
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both XCM and FGG
Number of subjects: 26
Study: 35264684

Group type: EXPERIMENTAL
Intervention: Chewing gum during preoperative fasting
Number of subjects: 94

Group type: COMPARATOR
Intervention: Conventional fasting
Number of subjects: 94
Study: 33213070

Group type: EXPERIMENTAL
Intervention: Vitamin C (Vit C)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Vitamin E (Vit E)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Melatonin (MT)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 97
Study: 35909001

Group type: COMPARATOR
Intervention: Breast milk plasmalogens (BM pPEs)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Maternal body mass index
Number of subjects: 39

Group type: COMPARATOR
Intervention: Maternal fatty acid intake, gestational age, and days postpartum
Number of subjects: 39
Study: 34900800

Group type: EXPERIMENTAL
Intervention: Low-intensity laser irradiation (LILI)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (conventional wound care)
Number of subjects: 75
Study: 35059703

Group type: EXPERIMENTAL
Intervention: DLPFC stimulation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 34
Study: 34694070

Group type: EXPERIMENTAL
Intervention: Combined metabolic activators (CMA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36158127

Group type: EXPERIMENTAL
Intervention: Specialized placement and PICC placement care
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine PICC placement and catheter maintenance
Number of subjects: 80
Study: 32372159

Group type: EXPERIMENTAL
Intervention: Epidermal vacuum wound dressing (VAC)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional wound care (CONV)
Number of subjects: 31
Study: 35550707

Group type: EXPERIMENTAL
Intervention: 6% Pueraria mirifica vaginal gel
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 72
Study: 34454883

Group type: EXPERIMENTAL
Intervention: Machine learning prediction model for CRT response
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Adaptive lasso model
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Participants in the 5th quintile of the prediction model
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Prediction model
Number of subjects: 741
Study: 33413491

Group type: EXPERIMENTAL
Intervention: Web-based menu planning intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 54
Study: 32081463

Group type: EXPERIMENTAL
Intervention: mirvetuximab soravtansine (6 mg/kg, adjusted ideal body weight) and bevacizumab (15 mg/kg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: mirvetuximab soravtansine and bevacizumab
Number of subjects: 66
Study: 36670359

Group type: EXPERIMENTAL
Intervention: Clarithromycin, esomeprazole, and amoxicillin
Number of subjects: 270

Group type: COMPARATOR
Intervention: Levofloxacin, esomeprazole, and amoxicillin
Number of subjects: 270
Study: 34407543

Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg once daily
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Ponatinib 30 mg once daily
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Ponatinib 15 mg once daily
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg and 30 mg (reduced to 15 mg upon response)
Number of subjects: 283
Study: 32928279

Group type: EXPERIMENTAL
Intervention: GV‐971 600 mg
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: GV‐971 900 mg
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 33538686

Group type: EXPERIMENTAL
Intervention: Prehospital continuous positive airway pressure (O‐Two system, O‐Two Medical Technologies Inc.)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard oxygen therapy, titrated to the British Thoracic Society's peripheral oxygen saturation targets
Number of subjects: 77
Study: 32320846

Group type: EXPERIMENTAL
Intervention: Telephone-based self-management support, including one face-to-face start-up session followed by telephone sessions.
Number of subjects: 4400

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 4400
Study: 34967444

Group type: EXPERIMENTAL
Intervention: Best Possible Medication History (BPMH) approach
Number of subjects: 372
Study: 34377501

Group type: EXPERIMENTAL
Intervention: Web application (digital tool)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Paper form (active control)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both tools (web app and paper form)
Number of subjects: 77
Study: 36322558

Group type: EXPERIMENTAL
Intervention: Perturbation‐based Balance Training (PBT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional Balance Training (CBT)
Number of subjects: 34
Study: 33242769

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched healthy subjects)
Number of subjects: 43
Study: 36099408

Group type: EXPERIMENTAL
Intervention: Preoperative respiratory therapy (EG)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 71
Study: 33813141

Group type: EXPERIMENTAL
Intervention: Flexyn2a bioconjugate vaccine
Number of subjects: 0
Study: 32027212

Group type: EXPERIMENTAL
Intervention: Early decompressive craniectomy
Number of subjects: 155

Group type: COMPARATOR
Intervention: Standard care (intensive medical therapies)
Number of subjects: 155
Study: 35766451

Group type: EXPERIMENTAL
Intervention: Bidirectional brace
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Elastic band
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Unidirectional brace
Number of subjects: 15
Study: 32869895

Group type: EXPERIMENTAL
Intervention: High-risk group (≥ 80 points)
Number of subjects: 9591

Group type: EXPERIMENTAL
Intervention: Moderate-risk group (50–79 points)
Number of subjects: 9591

Group type: COMPARATOR
Intervention: Low-risk group (30–49 points)
Number of subjects: 9591
Study: 35683562

Group type: EXPERIMENTAL
Intervention: Home adaptation (HA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Outpatient adaptation (OA)
Number of subjects: 66
Study: 32294874

Group type: COMPARATOR
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 123
Study: 36378059

Group type: EXPERIMENTAL
Intervention: Liu-zi-jue plus conventional therapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 104
Study: 33415873

Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication (1% lidocaine 4 mL after acupuncture)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Simple medication (1% lidocaine 30 mL)
Number of subjects: 60
Study: 33902152

Group type: EXPERIMENTAL
Intervention: Heavy-load (80% 1RM)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Light-load (40% 1RM)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no specific intervention)
Number of subjects: 15
Study: 33524439

Group type: EXPERIMENTAL
Intervention: Specific health warning labels (HWLs)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: General health warning labels (HWLs)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Non-warning control HWLs
Number of subjects: 63
Study: 35822682

Group type: EXPERIMENTAL
Intervention: Crocin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 33934988

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA)
Number of subjects: 746

Group type: COMPARATOR
Intervention: Volatile Anesthetics
Number of subjects: 746

Group type: COMPARATOR
Intervention: Volatile Anesthetics exposure quantified using area under the end-tidal expired anesthetic agent versus time curves
Number of subjects: 746
Study: 33150133

Group type: COMPARATOR
Intervention: nPPCI
Number of subjects: 1266

Group type: EXPERIMENTAL
Intervention: PPCI
Number of subjects: 1266
Study: 36106361

Group type: EXPERIMENTAL
Intervention: 67% sodium bicarbonate toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-sodium bicarbonate (regular) toothpaste
Number of subjects: 0
Study: 33047252

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 308
Study: 35236191

Group type: EXPERIMENTAL
Intervention: D‐dimer (D‐D) and fibrinogen (FIB) testing every 8 hours during catheter-directed thrombolysis (CDT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Venography and FIB testing every 24 hours during catheter-directed thrombolysis (CDT)
Number of subjects: 20
Study: 32895063

Group type: EXPERIMENTAL
Intervention: High smoker identity among dependent smokers
Number of subjects: 391

Group type: COMPARATOR
Intervention: Low smoker identity among dependent smokers
Number of subjects: 391

Group type: COMPARATOR
Intervention: Non-dependent smokers
Number of subjects: 391
Study: 33807102

Group type: EXPERIMENTAL
Intervention: 12 h time-restricted eating (TRE)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard dietary advice (SDA)
Number of subjects: 54
Study: 32326133

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise training (SupExT)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Attentional control (AC)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Post-intervention (6 months unsupervised)
Number of subjects: 219
Study: 34315439

Group type: EXPERIMENTAL
Intervention: Neoadjuvant everolimus plus letrozole for 18 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluorouracil, epirubicin plus cyclophosphamide (FEC) for 6 cycles
Number of subjects: 40
Study: 32929131

Group type: EXPERIMENTAL
Intervention: Pre-hypertension
Number of subjects: 9987

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 9987

Group type: EXPERIMENTAL
Intervention: Age-related hypertension
Number of subjects: 9987

Group type: EXPERIMENTAL
Intervention: Gender-related hypertension
Number of subjects: 9987

Group type: EXPERIMENTAL
Intervention: Uncontrolled hypertension
Number of subjects: 9987

Group type: EXPERIMENTAL
Intervention: 5-year incidence rate of pre-hypertension
Number of subjects: 9987

Group type: EXPERIMENTAL
Intervention: 5-year incidence rate of hypertension
Number of subjects: 9987

Group type: EXPERIMENTAL
Intervention: Overall hypertension control
Number of subjects: 9987
Study: 36098133

Group type: EXPERIMENTAL
Intervention: Bimagrumab 210 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Bimagrumab 700 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Bimagrumab 70 mg
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 32347763

Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg subcutaneously weekly or every 2 weeks)
Number of subjects: 2444

Group type: EXPERIMENTAL
Intervention: Dupilumab with concomitant topical corticosteroids (TCS)
Number of subjects: 2444

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2444

Group type: COMPARATOR
Intervention: Topical corticosteroids (TCS) alone
Number of subjects: 2444
Study: 34270825

Group type: EXPERIMENTAL
Intervention: Bortezomib consolidation (1.6 mg/m² IV on days 1, 8, 15, 22)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Observation (no bortezomib consolidation)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Double ASCT (without bortezomib consolidation)
Number of subjects: 340
Study: 35842816

Group type: EXPERIMENTAL
Intervention: Ivermectin/praziquantel (0.2 mg/kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Moxidectin/praziquantel (0.4 mg/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 36
Study: 33387588

Group type: EXPERIMENTAL
Intervention: High-fat meal rich in saturated fatty acids (SFA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-fat meal rich in monounsaturated fatty acids (MUFA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-fat meal rich in polyunsaturated fatty acids (PUFA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ad libitum buffet meal after 3 h postprandial period
Number of subjects: 16
Study: 35325108

Group type: EXPERIMENTAL
Intervention: CC‐486 (oral azacitidine) 300 mg daily in a 2 weeks on/2 weeks off schedule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35718216

Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention
Number of subjects: 21
Study: 35602344

Group type: EXPERIMENTAL
Intervention: Self-management education model based on protective motivation theory
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine nursing health education measures
Number of subjects: 90
Study: 33957695

Group type: COMPARATOR
Intervention: Randomized double-blind placebo-controlled clinical trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open label trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blinded trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommendations for blinding and design
Number of subjects: 0
Study: 35760082

Group type: EXPERIMENTAL
Intervention: Voluntary hyperventilation (VH) technique targeting an end‐tidal CO2 (ETCO2)<20 mmHg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Acetazolamide (AZ)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Voluntary hyperventilation (VH)
Number of subjects: 32
Study: 34097069

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) along with Pregabalin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 40
Study: 34380542

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS) tool
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 1145
Study: 33531467

Group type: EXPERIMENTAL
Intervention: Mental distancing from cigarettes (non-motor retraining)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control condition (suppressing or observing the image of a cigarette)
Number of subjects: 187
Study: 33990814

Group type: COMPARATOR
Intervention: 0% Brazil nut extract
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 25% Brazil nut extract
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 50% Brazil nut extract
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 75% Brazil nut extract
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 100% Brazil nut extract
Number of subjects: 5
Study: 35886690

Group type: EXPERIMENTAL
Intervention: END (endurance-trained group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: STR (strength-trained group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: CG (control group)
Number of subjects: 32
Study: 33070419

Group type: EXPERIMENTAL
Intervention: Tafamidis 80 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tafamidis 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33326711

Group type: EXPERIMENTAL
Intervention: HP-3070 7.6 mg/24 h
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: HP-3070 3.8 mg/24 h
Number of subjects: 614

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study: 35249270

Group type: EXPERIMENTAL
Intervention: Metformin add-on insulin therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 33186858

Group type: EXPERIMENTAL
Intervention: Gefitinib for 24 months
Number of subjects: 193

Group type: COMPARATOR
Intervention: Vinorelbine plus cisplatin (VP) every 3 weeks for four cycles
Number of subjects: 193
Study: 35973668

Group type: EXPERIMENTAL
Intervention: Riboflavin 50 mg daily
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Riboflavin 100 mg daily
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 33472913

Group type: EXPERIMENTAL
Intervention: Guadecitabine 20 mg/m2, days 1-5, combined with gemcitabine (1,000 mg/m2, i.v., days 8 + 15) and cisplatin (70 mg/m2, i.v., day 8)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Guadecitabine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Guadecitabine combined with gemcitabine and cisplatin
Number of subjects: 20
Study: 32873584

Group type: EXPERIMENTAL
Intervention: Clear plastic sheet covering the manikin
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Plexiglass intubation box over the manikin
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: No barrier
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control group (assistant)
Number of subjects: 5
Study: 35394800

Group type: EXPERIMENTAL
Intervention: selinexor (60 mg) twice weekly in 6-week cycles
Number of subjects: 285

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 285
Study: 34097045

Group type: EXPERIMENTAL
Intervention: HMGCR GRS equivalent to a 10‐mg/dL decrease in LDL cholesterol
Number of subjects: 53385

Group type: EXPERIMENTAL
Intervention: HMGCR GRS
Number of subjects: 53385
Study: 32688457

Group type: EXPERIMENTAL
Intervention: Modified scalp retractor
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional scalp retractor
Number of subjects: 32
Study: 35078407

Group type: EXPERIMENTAL
Intervention: Cognitively enhanced Tai Ji Quan
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard Tai Ji Quan
Number of subjects: 69

Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 69
Study: 33770114

Group type: EXPERIMENTAL
Intervention: Counseling during pre-discharge period
Number of subjects: 21280

Group type: EXPERIMENTAL
Intervention: Counseling during post-discharge period
Number of subjects: 21280

Group type: EXPERIMENTAL
Intervention: Counseling during both pre- and post-discharge periods
Number of subjects: 21280

Group type: COMPARATOR
Intervention: No counseling
Number of subjects: 21280
Study: 32605578

Group type: EXPERIMENTAL
Intervention: Bifidobacterium quadruple viable tablet
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 34275870

Group type: EXPERIMENTAL
Intervention: Standard demand creation (SDC)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Demand creation plus offer of HIV self-testing (HIVST)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Human-centred design (HCD)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: HCD-informed demand creation approach plus offer of HIVST
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: HCD alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Static (fixed) model
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Integrated (mobile) model
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 15
Study: 33040003

Group type: EXPERIMENTAL
Intervention: Personalised Nutrition Project algorithm-based diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-fat high-dietary fibre diet
Number of subjects: 0
Study: 35644973

Group type: EXPERIMENTAL
Intervention: 1sIPV+2bOPV
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: 2sIPV+1bOPV
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: 3sIPV
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: 2sIPV+1bOPV and 3sIPV
Number of subjects: 205